De Sanctis Vitaliana, Osti Mattia F, Berardi Francesca, Ardito Francesca, Valeriani Maurizio, Martelli Maurizio, Enrici Riccardo Maurizi
Radiotherapy Oncology, Department of Radiology, Università di Roma La Sapienza, Roma, Italy.
Anticancer Res. 2007 Jan-Feb;27(1B):601-5.
The treatment of primary cutaneous lymphoma is still ongoing and the role of radiotherapy, as exclusive or combined modality, is not yet clear.
From 1994 to June 2004, 29 patients with cutaneous B-cell lymphoma and 9 patients with cutaneous T-cell lymphoma were treated by radiotherapy (median dose of 3900 cGy, range 600-4600 cGy). Eight patients had previously received chemotherapy.
The complete response rate was 94.7% with progressive disease in two patients (5%). Sixteen (42.1%) patients relapsed, with the relapse occurring only in the skin site as single episode (9 patients) and more than two episodes (7 patients). The 5-year overall survival and event-free survival were 94% and 53%, respectively.
Radiotherapy offers a substantial local control of primary cutaneous lymphoma, both as exclusive or combined approach. The patients with wide-spread or multiple lesions, usually candidates for radiotherapy and chemotherapy, are amenable to radiotherapy alone.
原发性皮肤淋巴瘤的治疗仍在进行中，放疗作为单一或联合治疗方式的作用尚不清楚。
1994年至2004年6月，29例皮肤B细胞淋巴瘤患者和9例皮肤T细胞淋巴瘤患者接受了放疗（中位剂量3900 cGy，范围600 - 4600 cGy）。8例患者此前接受过化疗。
完全缓解率为94.7%，2例患者（5%）出现疾病进展。16例（42.1%）患者复发，复发仅发生在皮肤部位，单次复发（9例）和超过两次复发（7例）。5年总生存率和无事件生存率分别为94%和53%。
放疗作为单一或联合治疗方法，对原发性皮肤淋巴瘤具有显著的局部控制效果。对于广泛或多发病变的患者，通常适合放疗和化疗，单独放疗也是可行的。
